Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3

Oncogene

Volumn 34, Issue 16, 2014, Pages 2032-2042

  Robichaud, N ^a   Del Rincon, S V ^b   Huor, B ^b   Alain, T ^c   Petruccelli, L A ^b   Hearnden, J ^a   Goncalves, C ^b   Grotegut, S ^d   Spruck, C H ^d   Furic, L ^e   Larsson, O ^f   Muller, W J ^a   Miller, W H ^b   Sonenberg, N ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^d BURNHAM INSTITUTE   (United States)

^e MONASH UNIVERSITY   (Australia)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E; MESSENGER RNA; MMP3 PROTEIN, MOUSE; SNAIL FAMILY TRANSCRIPTION FACTORS; STROMELYSIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; BIOSYNTHESIS; CELL MOTION; CELL TRANSFORMATION; EPITHELIAL MESENCHYMAL TRANSITION; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENETICS; LUNG TUMOR; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; PROTEIN SYNTHESIS; SECONDARY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL-MESENCHYMAL TRANSITION; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MATRIX METALLOPROTEINASE 3; MICE; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84929372129     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.146     Document Type: Article

References (82)

1. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: Mechanisms and biological targets. Cell 2009; 136: 731-745.
2. Hiremath LS, Webb NR, Rhoads RE. Immunological detection of the messenger RNA cap-binding protein. J Biol Chem 1985; 260: 7843-7849.
3. Duncan R, Milburn SC, Hershey JW. Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF-4F. J Biol Chem 1987; 262: 380-388.
4. Pause A, Belsham GJ, Gingras AC, Donze O, Lin TA, Lawrence Jr. JC et al. Insulindependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. Nature 1994; 371: 762-767.
5. Poulin F, Gingras AC, Olsen H, Chevalier S, Sonenberg N. 4E-BP3, a new member of the eukaryotic initiation factor 4E-binding protein family. J Biol Chem 1998; 273: 14002-14007.
6. Flynn A, Proud CG. Serine 209, not serine 53, is the major site of phosphorylation in initiation factor eIF-4E in serum-treated Chinese hamster ovary cells. J Biol Chem 1995; 270: 21684-21688.
7. Joshi B, Cai AL, Keiper BD, Minich WB, Mendez R, Beach CM et al. Phosphorylation of eukaryotic protein synthesis initiation factor 4E at Ser-209. J Biol Chem 1995; 270: 14597-14603.
8. Waskiewicz AJ, Johnson JC, Penn B, Mahalingam M, Kimball SR, Cooper JA. Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol Cell Biol 1999; 19: 1871-1880.
9. Pyronnet S, Imataka H, Gingras AC, Fukunaga R, Hunter T, Sonenberg N. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J 1999; 18: 270-297.
10. Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature 1990; 345: 544-547.
11. Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004; 10: 484-486.
12. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T et al. Dissecting eIF4E action in tumorigenesis. Genes Dev 2007; 21: 3232-3237.
13. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N. eIF4E-from translation to transformation. Oncogene 2004; 23: 3172-3179.
14. Lee T, Pelletier J Eukaryotic initiation factor 4F: A vulnerability of tumor cells. Future Med Chem 2012; 4: 19-31.
15. Jia Y, Polunovsky V, Bitterman PB, Wagner CR. Cap-dependent translation initiation factor eIF4E: An emerging anticancer drug target. Med Res Rev 2012; 32: 786-814.
16. Malina A, Mills JR, Pelletier J. Emerging therapeutics targeting mRNA translation. Cold Spring Harb Perspect Biol 2012; 4: A012377.
17. Topisirovic I, Ruiz-Gutierrez M, Borden KL. Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res 2004; 64: 8639-8642.
18. Ueda T, Sasaki M, Elia AJ, Chio II, Hamada K, Fukunaga R et al. Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci USA 2010; 107: 13984-13990.
19. Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, Dumstorf CA et al. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res 2011; 71: 1849-1857.
20. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004; 23: 3189-3199.
21. Nasr Z, Robert F, Porco JA, Muller WJ, Pelletier J. eIF4F suppression in breast cancer affects maintenance and progression. Oncogene 2012; 32: 861-871.
22. Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvey H, Puckett R et al. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clin Cancer Res 2011; 17: 2874-2884.
23. Graff JR, Konicek BW, Lynch RL, Dumstorf CA, Dowless MS, McNulty AM et al. eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res 2009; 69: 3866-3873.
24. Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A et al. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci USA 2010; 107: 14134-14139.
25. Li L, Price JE, Fan D, Zhang RD, Bucana CD, Fidler IJ. Correlation of growth capacity of human tumor cells in hard agarose with their in vivo proliferative capacity at specific metastatic sites. J Natl Cancer Inst 1989; 81: 1406-1412.
26. Friedl P, Alexander S. Cancer invasion and the microenvironment: Plasticity and reciprocity. Cell 2011; 147: 992-1009.
27. Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 1997; 139: 1861-1872.
28. DaSilva J, Xu L, Kim HJ, Miller WT, Bar-Sagi D. Regulation of sprouty stability by Mnk1-dependent phosphorylation. Mol Cell Biol 2006; 26: 1898-1907.
29. Hefner Y, Borsch-Haubold AG, Murakami M, Wilde JI, Pasquet S, Schieltz D et al. Serine 727 phosphorylation and activation of cytosolic phospholipase A2 by MNK1-related protein kinases. J Biol Chem 2000; 275: 37542-37551.
30. Guil S, Long JC, Caceres JF. hnRNPA1 relocalization to the stress granules reflects a role in the stress response. Mol Cell Biol 2006; 26: 5744-5758.
31. Buxade M, Parra JL, Rousseau S, Shpiro N, Marquez R, Morrice N et al. The Mnks are novel components in the control of TNF alpha biosynthesis and phosphorylate and regulate hnRNPA1. Immunity 2005; 23: 177-189.
32. Byers HR, Etoh T, Doherty JR, Sober AJ, Mihm Jr. MC. Cell migration and actin organization in cultured human primary, recurrent cutaneous and metastatic melanoma. Time-lapse and image analysis. Am J Pathol 1991; 139: 423-435.
33. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987; 47: 3239-3245.
34. Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP. Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 1994; 31: 325-335.
35. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012; 485: 55-61.
36. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
37. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37: 1-13.
38. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428.
39. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009; 19: 156-172.
40. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009; 119: 1429-1437.
41. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res 2009; 19: 128-139.
42. Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL. p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 2002; 115: 3193-3206.
43. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002; 62: 65-74.
44. Imamura T, Hikita A, Inoue Y. The roles of TGF-beta signaling in carcinogenesis and breast cancer metastasis. Breast Cancer 2012; 19: 118-124.
45. Knauf U, Tschopp C, Gram H. Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol Cell Biol 2001; 21: 5500-5511.
46. Scheper GC, Morrice NA, Kleijn M, Proud CG. The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells. Mol Cell Biol 2001; 21: 743-754.
47. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992; 52: 1399-1405.
48. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol Cell Biol 1992; 12: 954-961.
49. Dilworth SM. Polyoma virus middle T antigen and its role in identifying cancerrelated molecules. Nat Rev Cancer 2002; 2: 951-956.
50. Franci C, Takkunen M, Dave N, Alameda F, Gomez S, Rodriguez R et al. Expression of Snail protein in tumor-stroma interface. Oncogene 2006; 25: 5134-5144.
51. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996; 149: 273-282.
52. Li BD, McDonald JC, Nassar R, De Benedetti A. Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. Ann Surg 1998; 227: 756-6l discussion 61-3.
53. Li BD, Gruner JS, Abreo F, Johnson LW, Yu H, Nawas S et al. Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome. Ann Surg 2002; 235: 732-738 discussion 8-9.
54. Holm N, Byrnes K, Johnson L, Abreo F, Sehon K, Alley J et al. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-negative breast cancer. Ann Surg Oncol 2008; 15: 3207-3215.
55. McClusky DR, Chu Q, Yu H, Debenedetti A, Johnson LW, Meschonat C et al. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer. Ann Surg 2005; 242: 584-590 discussion 90-2.
56. Crew JP, Fuggle S, Bicknell R, Cranston DW, de Benedetti A, Harris AL. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br J Cancer 2000; 82: 161-166.
57. Seki N, Takasu T, Mandai K, Nakata M, Saeki H, Heike Y et al. Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. Clin Cancer Res 2002; 8: 3046-3053.
58. Seki N, Takasu T, Sawada S, Nakata M, Nishimura R, Segawa Y et al. Prognostic significance of expression of eukaryotic initiation factor 4E and 4E binding protein in patients with pathological stage I invasive lung adenocarcinoma. Lung Cancer 2010; 70: 329-334.
59. Nathan CO, Franklin S, Abreo FW, Nassar R, De Benedetti A, Glass J. Analysis of surgical margins with the molecular marker eIF4E: A prognostic factor in patients with head and neck cancer. J Clin Oncol 1999; 17: 2909-2914.
60. Wu M, Liu Y, Di X, Kang H, Zeng H, Zhao Y et al. EIF4E over-expresses and enhances cell proliferation and cell cycle progression in nasopharyngeal carcinoma. Med Oncol 2013; 30: 400.
61. Wang XL, Cai HP, Ge JH, Su XF. Detection of eukaryotic translation initiation factor 4E and its clinical significance in hepatocellular carcinoma. World J Gastroenterol 2012; 18: 2540-2544.
62. Salehi Z, Mashayekhi F. Expression of the eukaryotic translation initiation factor 4E (eIF4E) and 4E-BP1 in esophageal cancer. Clin Biochem 2006; 39: 404-409.
63. Chen CN, Hsieh FJ, Cheng YM, Lee PH, Chang KJ. Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome. J Surg Oncol 2004; 86: 22-27.
64. Nathan CO, Carter P, Liu L, Li BD, Abreo F, Tudor A et al. Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas. Oncogene 1997; 15: 1087-1094.
65. Scott PA, Smith K, Poulsom R, De Benedetti A, Bicknell R, Harris AL. Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E. Br J Cancer 1998; 77: 2120-2128.
66. Byrnes K, White S, Chu Q, Meschonat C, Yu H, Johnson LW et al. High eIF4E, VEGF, and microvessel density in stage I to III breast cancer. Ann Surg 2006; 243: 684-690.
67. Fan S, Ramalingam SS, Kauh J, Xu Z, Khuri FR, Sun SY. Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol Ther 2009; 8: 1463-1469.
68. Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks TJ, Hewitt SM et al. Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res 2010; 16: 240-248.
69. Zheng J, Li J, Xu L, Xie G, Wen Q, Luo J et al. Phosphorylated Mnk1 and eIF4E are associated with lymph node metastasis and poor prognosis of nasopharyngeal carcinoma. PLoS ONE 2014; 9: E89220.
70. Ferrandiz-Pulido C, Masferrer E, Toll A, Hernandez-Losa J, Mojal S, Pujol RM et al. mTOR signaling pathway in penile squamous cell carcinoma: PmTOR and peIF4E over expression correlate with aggressive tumor behavior. J Urol 2013; 190: 2288-2295.
71. Adesso L, Calabretta S, Barbagallo F, Capurso G, Pilozzi E, Geremia R et al. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway. Oncogene 2013; 32: 2848-2857.
72. Grzmil M, Morin P Jr, Lino MM, Merlo A, Frank S, Wang Y et al. MAP kinaseinteracting kinase 1 regulates SMAD2-dependent TGF-beta signaling pathway in human glioblastoma. Cancer Res 2011; 71: 2392-2402.
73. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65: 7052-7058.
74. Yin B, Morgan K, Hasz DE, Mao Z, Largaespada DA. Nfl gene inactivation in acute myeloid leukemia cells confers cytarabine resistance through MAPK and mTOR pathways. Leukemia 2006; 20: 151-154.
75. Astanehe A, Finkbeiner MR, Krzywinski M, Fotovati A, Dhillon J, Berquin IM et al. MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition. Oncogene 2012; 31: 4434-4446.
76. Ramón y Cajal, Rojo S, Pone S, Castellana B, Hernandez Losa B, Sonenberg J et al. Clinical Translational Oncology (in press).
77. C.S.H. Laboratory, RIPA buffer (05-01). Cold Spring Harbor Protocols, 2006. 2006(4): P. pdb.rec10617. http://cshprotocols.cshlp.org/content/2006/4/pdb.rec10617.short.
78. Ling C, Su VM, Zuo D, Muller WJ. Loss of the 14-3-3sigma tumor suppressor is a critical event in ErbB2-mediated tumor progression. Cancer Discov 2012; 2: 68-81.
79. Alain T, Morita M, Fonseca BD, Yanagiya A, Siddiqui N, Bhat M et al. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res 2012; 72: 6468-6476.
80. Larsson O, Sonenberg N, Nadon R. Anota: Analysis of differential translation in genome-wide studies. Bioinformatics 2011; 27: 1440-1441.
81. Larsson O, Sonenberg N, Nadon R. Identification of differential translation in genome wide studies. Proc Natl Acad Sci USA 2010; 107: 21487-21492.
82. Huang da W, Sherman BT, Zheng X, Yang J, Imamichi T, Stephens R et al. Extracting biological meaning from large gene lists with DAVID. Curr Protoc Bioinformatics 2009. Chapter 13: Unit 13.